{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:56:01Z","timestamp":1760954161191},"reference-count":102,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/spc.0b013e328349dc17","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:45:52Z","timestamp":1371159952000},"page":"233-240","source":"Crossref","is-referenced-by-count":23,"title":["Antitumor effects of bisphosphonates"],"prefix":"10.1097","volume":"5","author":[{"given":"James R.","family":"Berenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20211004","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group.","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-9-20211004","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up from two randomized, placebo-controlled trials.","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"R3-9-20211004","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"R4-9-20211004","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"R5-9-20211004","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid in for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R6-9-20211004","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial.","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"R7-9-20211004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.leu.2400892","article-title":"In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.","volume":"12","author":"Aparicio","year":"1998","journal-title":"Leukemia"},{"key":"R8-9-20211004","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","article-title":"Bisphosphonates induce breast cancer death in vitro.","volume":"15","author":"Fromigue","year":"2000","journal-title":"J Bone Miner Res"},{"key":"R9-9-20211004","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines.","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"key":"R10-9-20211004","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.ju.0000070685.34760.5f","article-title":"Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.","volume":"170","author":"Oades","year":"2003","journal-title":"J Urol"},{"key":"R11-9-20211004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"R12-9-20211004","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"R13-9-20211004","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1luc mouse breast cancer model.","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R14-9-20211004","first-page":"4418","article-title":"The bisphosphonate ibandronate promotes apoptosis in MDA-MD-231 human breast cancer cells in bone metastases.","volume":"61","author":"Hiraga","year":"2001","journal-title":"Cancer Res"},{"key":"R15-9-20211004","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0002-9440(10)63239-7","article-title":"Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial cell signaling.","volume":"165","author":"Yamagishi","year":"2004","journal-title":"Am J Pathol"},{"key":"R16-9-20211004","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/1078-0432.CCR-05-2050","article-title":"The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.","volume":"12","author":"Yang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R17-9-20211004","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-05-2766","article-title":"Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.","volume":"12","author":"Wakchoure","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R18-9-20211004","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/cncr.21530","article-title":"Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.","volume":"104","author":"Ory","year":"2005","journal-title":"Cancer"},{"key":"R20-9-20211004","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/cncr.21383","article-title":"Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.","volume":"104","author":"Zhou","year":"2005","journal-title":"Cancer"},{"key":"R21-9-20211004","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/pros.20776","article-title":"Zoledronic acid decreased osteolysis but not bone metastases in a nude mouse model of canine prostate cancer with mixed bone lesions.","volume":"68","author":"Thudi","year":"2008","journal-title":"Prostate"},{"key":"R22-9-20211004","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"key":"R23-9-20211004","first-page":"5452","article-title":"Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats.","volume":"53","author":"Kostenuik","year":"1993","journal-title":"Cancer Res"},{"key":"R24-9-20211004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.","volume":"99","author":"Daubine","year":"2007","journal-title":"J Natl Cancer Instit"},{"key":"R25-9-20211004","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","article-title":"Zoledronic acid: a new adjuvant therapeutic strategy for Ewings sarcoma patients.","volume":"70","author":"Odri","year":"2010","journal-title":"Cancer Res"},{"key":"R26-9-20211004","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bone.2009.01.010","article-title":"The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.","volume":"44","author":"Hirbe","year":"2009","journal-title":"Bone"},{"key":"R27-9-20211004","first-page":"2147","article-title":"Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.","volume":"28","author":"Murayama","year":"2008","journal-title":"Anticancer Res"},{"key":"R29-9-20211004","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1158\/1078-0432.CCR-05-1010","article-title":"Effect of combination therapy with a novel bisphosphonate. minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.","volume":"11","author":"Inoue","year":"2005","journal-title":"Clin Caner Res"},{"key":"R30-9-20211004","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1158\/1078-0432.CCR-07-1545","article-title":"Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast cancer growth in vivo.","volume":"14","author":"Ottewell","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R31-9-20211004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-008-0236-6","article-title":"Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.","volume":"118","author":"van Beek","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"R33-9-20211004","first-page":"5380","article-title":"Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell ling cancer cells in severe combined immunodeficient mice.","volume":"9","author":"Yano","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R34-9-20211004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2401770","article-title":"Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines.","volume":"14","author":"Tassone","year":"2000","journal-title":"Leukemia"},{"key":"R35-9-20211004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF02983818","article-title":"The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.","volume":"78","author":"Ural","year":"2003","journal-title":"Int J Hematol"},{"key":"R36-9-20211004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.exphem.2010.10.005","article-title":"The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.","volume":"39","author":"Abeltino","year":"2011","journal-title":"Exp Hematol"},{"key":"R37-9-20211004","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/sj.bjc.6605579","article-title":"Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole in breast cancer cells in vitro; evidence of synergistic interaction.","volume":"102","author":"Neville-Webbe","year":"2010","journal-title":"Br J Cancer"},{"key":"R38-9-20211004","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood-2003-01-0305","article-title":"The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph leukemia activity of imatinib mesylate.","volume":"102","author":"Kuoda","year":"2003","journal-title":"Blood"},{"key":"R39-9-20211004","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/sj.leu.2403949","article-title":"Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.","volume":"19","author":"Chuah","year":"2005","journal-title":"Leukemia"},{"key":"R40-9-20211004","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/0008-5472.CAN-04-3601","article-title":"Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.","volume":"65","author":"Kim","year":"2005","journal-title":"Cancer Res"},{"key":"R41-9-20211004","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1158\/1535-7163.MCT-07-0221","article-title":"Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonates zoledronic acid against cancer cells in vitro.","volume":"6","author":"Sonneman","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"R42-9-20211004","doi-asserted-by":"crossref","first-page":"10239","DOI":"10.1158\/0008-5472.CAN-10-0578","article-title":"Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (everolimus): pivotal role of the prenylation process.","volume":"70","author":"Moriceau","year":"2010","journal-title":"Cancer Res"},{"key":"R43-9-20211004","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-09-2904","article-title":"Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.","volume":"16","author":"Zhang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R44-9-20211004","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1359\/jbmr.1998.13.11.1668","article-title":"Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"R45-9-20211004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacokinetic and pharmacodynamic properties of statins.","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol Ther"},{"key":"R46-9-20211004","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","article-title":"From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.","volume":"75","author":"Rogers","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"R47-9-20211004","first-page":"105301058","article-title":"Effects of an HMG-CoA reductase, simvastatin, on human myeloma cells.","volume":"11","author":"Otsuki","year":"2004","journal-title":"Oncol Rep"},{"key":"R48-9-20211004","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/sj.leu.2402501","article-title":"The cholesterol lower drug lovastatin induces cell death in myeloma plasma cells.","volume":"16","author":"van de Donk","year":"2002","journal-title":"Leukemia"},{"key":"R49-9-20211004","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/01.cad.0000215058.85813.02","article-title":"Synergistic antimyeloma effects of zoledronate and simvastatin.","volume":"17","author":"Schmidmaier","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"R50-9-20211004","doi-asserted-by":"crossref","first-page":"9109","DOI":"10.1158\/0008-5472.CAN-05-2635","article-title":"Recent advances in understanding the antineoplastic mechanisms of farnesyl transferase inhibitors.","volume":"65","author":"Pan","year":"2005","journal-title":"Cancer Res"},{"key":"R51-9-20211004","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1158\/0008-5472.CAN-05-3416","article-title":"Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.","volume":"66","author":"Efuet","year":"2006","journal-title":"Cancer Res"},{"key":"R52-9-20211004","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1538-7836.2006.02259.x","article-title":"Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways.","volume":"5","author":"Hasmim","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R53-9-20211004","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6600986","article-title":"Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"R54-9-20211004","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10495-008-0211-z","article-title":"The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis.","volume":"13","author":"Sewing","year":"2008","journal-title":"Apoptosis"},{"key":"R55-9-20211004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/1477-3163.75723","article-title":"Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers.","volume":"10","author":"Almubarak","year":"2011","journal-title":"J Carcinog"},{"key":"R56-9-20211004","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/mol.106.028837","article-title":"Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.","volume":"71","author":"Ory","year":"2007","journal-title":"Mol Pharmacol"},{"key":"R57-9-20211004","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10585-010-9342-z","article-title":"Nitrogen-containing bisphosphonate, YM529ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the RhoROCK pathway.","volume":"27","author":"Tanimori","year":"2010","journal-title":"Clin Exp Metastasis"},{"key":"R58-9-20211004","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1074\/jbc.M109.038935","article-title":"Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in follicular lymphoma cells.","volume":"285","author":"Mitrofan","year":"2010","journal-title":"J Biol Chem"},{"key":"R60-9-20211004","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"R61-9-20211004","first-page":"71","article-title":"A novel angiogenesis model for screening antiangiogenic compounds: the chorioallantoic membranefeather bud assay.","volume":"37","author":"Chen","year":"2010","journal-title":"Int J Oncol"},{"key":"R62-9-20211004","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"key":"R63-9-20211004","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejca.2009.10.019","article-title":"Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patient with multiple myeloma.","volume":"46","author":"Moschetta","year":"2010","journal-title":"Eur J Cancer"},{"key":"R64-9-20211004","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenic factors in cancer patients.","volume":"8","author":"Santini","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R65-9-20211004","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R66-9-20211004","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","article-title":"Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.","volume":"98","author":"Van der Pluijm","year":"1996","journal-title":"J Clin Invest"},{"key":"R67-9-20211004","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"key":"R68-9-20211004","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.21104","article-title":"Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.","volume":"104","author":"Corso","year":"2005","journal-title":"Cancer"},{"key":"R69-9-20211004","first-page":"2708","article-title":"Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.","volume":"62","author":"Virtanen","year":"2002","journal-title":"Cancer Res"},{"key":"R70-9-20211004","first-page":"6015","article-title":"Alendronate inhibits lysophatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho.","volume":"62","author":"Sawada","year":"2002","journal-title":"Cancer Res"},{"key":"R71-9-20211004","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"R72-9-20211004","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/sj.bjc.6600925","article-title":"New insights into the actions of bisphosphonates zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.","volume":"88","author":"Denoyelle","year":"2003","journal-title":"Br J Cancer"},{"key":"R73-9-20211004","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1158\/0008-5472.CAN-05-0540","article-title":"The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.","volume":"65","author":"Miwa","year":"2005","journal-title":"Cancer Res"},{"key":"R75-9-20211004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1023\/A:1006524610591","article-title":"Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice.","volume":"16","author":"Stearns","year":"1998","journal-title":"Clin Exp Metastasis"},{"key":"R76-9-20211004","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","article-title":"Amino-bisphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.","volume":"67","author":"Melani","year":"2007","journal-title":"Cancer Res"},{"key":"R77-9-20211004","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1349-7006.2007.00651.x","article-title":"Nitrogen-containing bisphosphonate, YM529ONO-5920, inhibits macrophage inflammatory protein 1 expression and secretion in mouse myeloma cells.","volume":"99","author":"Tsubaki","year":"2008","journal-title":"Cancer Sci"},{"key":"R78-9-20211004","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein 1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"R79-9-20211004","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells.","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"key":"R80-9-20211004","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/1535-7163.MCT-10-0836","article-title":"CCN1, a candidate target for zoledronic acid treatment in breast cancer.","volume":"10","author":"Espinoza","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"R81-9-20211004","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384","article-title":"Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"R82-9-20211004","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbrc.2004.11.075","article-title":"Alternative bisphosphonate targets and mechanisms of action.","volume":"328","author":"Bukowski","year":"2005","journal-title":"Biochem Biophys Res Comm"},{"key":"R83-9-20211004","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.","volume":"37","author":"Abe","year":"2009","journal-title":"Exp Hematol"},{"key":"R84-9-20211004","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bbrc.2007.01.031","article-title":"Gamma delta T cells kill myeloma cells by sensing mevalonic acid metabolites and ICAM-1 molecules on cell surface.","volume":"354","author":"Uchida","year":"2007","journal-title":"Biochem Biophys Res Comm"},{"key":"R85-9-20211004","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of Vgamma9delta2 T cells with zoledronate and interleukin 2 for immunotherapy of advanced breast cancer patients.","volume":"161","author":"Meriviglia","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"R86-9-20211004","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"R88-9-20211004","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-2141.1998.00976.x","article-title":"Antimyeloma activity of pamidronate in vivo.","volume":"103","author":"Dhodapkar","year":"1998","journal-title":"Br J Haematol"},{"key":"R89-9-20211004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma.","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"R90-9-20211004","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events.","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"R92-9-20211004","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","article-title":"Antitumor activity of zoledronic acid in previously untreated patients with multiple myeloma.","volume":"24","author":"Aviles","year":"2007","journal-title":"Med Oncol"},{"key":"R93-9-20211004","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"R94-9-20211004","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.","volume":"52","author":"DArena","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R95-9-20211004","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"Fist-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial.","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"R96-9-20211004","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"R97-9-20211004","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R98-9-20211004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am J Hematol"},{"key":"R99-9-20211004","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood.V112.11.2783.2783","article-title":"Parathyroid hormone (PTH) serum variations are associated with bortezomib response in multiple myeloma patients.","volume":"112","author":"Zangari","year":"2008","journal-title":"Blood"},{"key":"R100-9-20211004","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","article-title":"Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma disease in the 5T2MM murine model of myeloma.","volume":"69","author":"Deleu","year":"2009","journal-title":"Cancer Res"},{"key":"R101-9-20211004","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"key":"R102-9-20211004","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1532\/IJH97.07030","article-title":"Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.","volume":"86","author":"Ozaki","year":"2007","journal-title":"Int J Hematol"},{"key":"R103-9-20211004","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","article-title":"Thalidomide derivative CC-4047 inhibits osteoclast formation by downregulation of PU.1.","volume":"107","author":"Anderson","year":"2006","journal-title":"Blood"},{"key":"R104-9-20211004","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"R105-9-20211004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ajh.21912","article-title":"Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.","volume":"86","author":"Berenson","year":"2011","journal-title":"Am J Hematol"},{"key":"R106-9-20211004","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4161\/cbt.10.6.12611","article-title":"Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients.","volume":"10","author":"Facchini","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"R107-9-20211004","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.","volume":"96","author":"Horie","year":"2007","journal-title":"Br J Cancer"},{"key":"R108-9-20211004","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.25744","article-title":"Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.","volume":"117","author":"Meyers","year":"2011","journal-title":"Cancer"},{"key":"R109-9-20211004","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2407-10-462","article-title":"Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone.","volume":"10","author":"Balke","year":"2010","journal-title":"BMC Cancer"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201109000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T10:33:11Z","timestamp":1715509991000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201109000-00009"}},"subtitle":["from the laboratory to the clinic"],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e328349dc17","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}